Curated News
By: NewsRamp Editorial Staff
June 12, 2024
Clene Inc. to Present at 72nd Emerging Growth Conference
Discuss on RedditTLDR
- Clene (NASDAQ: CLNN) to present at the Emerging Growth Conference, showcasing potential for long-term growth and strong management teams.
- Clene's President and CEO Rob Etherington and CFO Morgan Brown to provide a keynote speech on June 12 at 2:20 p.m. ET.
- Clene is focused on improving mitochondrial health and treating neurodegenerative diseases, aiming to make tomorrow better for patients with ALS, Parkinson's, and MS.
- CNM-Au8® is an investigational therapy that targets mitochondrial function and reduces oxidative stress, offering innovative potential for the treatment of neurodegenerative diseases.
Impact - Why it Matters
This news matters as it highlights Clene's participation in a major conference and underscores the potential of its investigational therapy in treating neurodegenerative diseases. Investors and individuals interested in medical advancements should take note of this event.
Summary
Clene (NASDAQ: CLNN) will be presenting at the 72nd Emerging Growth Conference, where President and CEO Rob Etherington and CFO Morgan Brown will deliver a keynote speech on June 12. The event aims to highlight companies with strong management, innovative products, and long-term growth potential.
Clene is a late clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its investigational therapy, CNM-Au8®, targets mitochondrial function and the NAD pathway to improve neuronal function and reduce oxidative stress. For more information, visit www.Clene.com.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. to Present at 72nd Emerging Growth Conference
